Status:
COMPLETED
Evaluation of Gastric Content of Volunteers Fasting and Using Semaglutide: an Observational and Cross-sectional Study
Lead Sponsor:
Hospital Israelita Albert Einstein
Conditions:
Pneumonia, Aspiration
Anesthesia
Eligibility:
All Genders
18+ years
Brief Summary
Medicines with peptide-1 receptor agonist action similar to glucagon (GLP-1) are a modern therapeutic option for obesity and diabetes mellitus. Semaglutide is a representative of this class medication...
Detailed Description
INTRODUCTION Obesity and type 2 diabetes mellitus constitute a global public health problem. Medications with glucagon-like peptide-1(GLP-1) receptor agonist action are a modern therapeutic option fo...
Eligibility Criteria
Inclusion
- • Adult individuals (aged 18 or over).
- Individuals currently using semaglutide.
- Individuals fasting for at least 8 hours for solids and 2 hours for clear liquids without residue.
Exclusion
- Pregnant women and postpartum women.
- Individuals with technical limitations to perform gastric content assessment using ultrasonography
- Presence of risk factors for gastroparesis.
- Use of drugs from the prokinetic class, which accelerate gastric emptying, such as bromopride, metoclopramide and domperidone.
Key Trial Info
Start Date :
June 19 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 22 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06154486
Start Date
June 19 2023
End Date
August 22 2023
Last Update
December 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Israelita Albert Einstein
São Paulo, Brazil, 05652900